Physician profile
Brian Jackson
NPI 1790560589
$5,893.14
in general payments reported to CMS, 2019-2025
23 companies · $3,085 in 2025
The $3,085 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $118 · 2024: $2,690 · 2025: $3,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,893.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,829.23 | 2023-2025 | |
| Janssen Biotech, INC. | $962.45 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $700.05 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Regeneron Healthcare Solutions, INC. | $511.91 | 2023-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $380.32 | 2024-2025 | Zenpep |
| Gilead Sciences, INC. | $320.76 | 2024-2025 | Livdelzi |
| Lilly USA, LLC | $240.90 | 2024-2025 | Omvoh, Zepbound |
| Madrigal Pharmaceuticals | $182.14 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.61 | 2024-2025 | Xifaxan, Trulance |
| Ipsen Biopharmaceuticals, INC | $81.85 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $81.74 | 2024-2025 | Voquezna |
| Pfizer INC. | $75.99 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $65.26 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $58.28 | 2024 | Dificid |
| Organon LLC | $57.45 | 2024-2025 | Renflexis, Hadlima |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $45.46 | 2024 | |
| Ardelyx, INC. | $43.13 | 2025 | Ibsrela |
| Haemonetics Corporation | $30.37 | 2024 | Teg6s Hemostasis System |
| Ironwood Pharmaceuticals, INC | $29.00 | 2024 | |
| Glaxosmithkline, LLC. | $24.78 | 2024 | Nucala |
| Atricure, INC. | $17.12 | 2025 | Atriclip Laa Exclusion System |
| Nestle Healthcare Nutrition INC. | $15.69 | 2023 | |
| Boston Scientific Corporation | $12.65 | 2025 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.